Editors' picks from other sources

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Drug interactions and pharmacokinetics news

Show

From To
New and experimental hepatitis C treatment
No critical interactions between ledipasvirsofosbuvir and certain key antiretrovirals

Ledipasvir/sofosbuvir, a fixed-dose coformulation of two direct-acting antivirals (DAAs) for HCV infection, did not have a clinically significant impact on five frequently used antiretrovirals--raltegravir, efavirenz, rilpivirine, and tenofovir/emtricitabine (TDF/FTC)--according to results of three studies in healthy volunteers.

Published
29 May 2014
From
NATAP
Drug interactions and pharmacokinetics
Calcium and Iron Supplements Lower Dolutegravir Levels When Taken Between Meals

Calcium supplements taken with dolutegravir between meals lowered dolutegravir exposure by one third. Iron supplements with dolutegravir between meals approximately halved dolutegravir exposure. Supplements did not have this effect when taken with dolutegravir with a meal, or when dolutegravir was taken 2 hours before the supplement.

Published
24 May 2014
From
NATAP
Drug interactions and pharmacokinetics
Better Late Than Never: Efavirenz Dose Optimization

After a study suggests that we’ve been using too high a dose of efavirenz for a decade and a half, the move toward scaling up a lower and more cost-effective one faces some hurdles.

Published
03 April 2014
From
Treatment Action Group
TB treatment
Announcement: Updated Guidelines on Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis

The updated guidelines include recommendations for use of newer antiretroviral drugs, including those in new classes, such as CCR5 receptor antagonists and integrase inhibitors. The new guidelines provide additional recommendations regarding use of rifampin with antiretroviral therapy; these recommendations are critical in regions where rifabutin is unavailable.

Published
31 March 2014
From
Morbidity and Mortality Weekly Report
Nutrition
Malnutrition decreases effectiveness of HIV treatment in pregnant African women

In Uganda the prescription of three antiretroviral drugs, which aim to suppress the virus to prevent disease progression, have resulted in huge reductions in HIV mortality rates. However, disease is not the only scourge in Uganda, and a new study in The Journal of Clinical Pharmacology explores the impact food insecurity may have on treating pregnant women.

Published
19 February 2014
From
Eurekalert Medicine & Health
Hepatitis C treatment
Victrelis (boceprevir) label changes update contraindications and drug interactions

On January 17, 2014, FDA approved changes to the Victrelis (boceprevir) package insert to expand the list of contraindicated medications and update the Drug Interaction section.

Published
23 January 2014
From
FDA
Drug interactions and pharmacokinetics
Risk of Harmful Drug Interactions Rises With Age in HIV+ US Group

Every 10 years of age independently raised chances that a person in a US HIV cohort would be prescribed an antiretroviral and a nonantiretroviral that should not be given together. One third of cohort members were prescribed medications with moderate or high evidence of a possible drug-drug interaction.

Published
26 November 2013
From
International AIDS Society
Drug interactions and pharmacokinetics
Merck plans phase III study of once-daily raltegravir (Isentress)

The poster presentation A Single Dose Food Effect Study of Raltegravir Formulations (Poster #PE10/17) will be presented Thursday, Oct. 17, and Friday, Oct. 18, from 12:00 p.m. to 2:00 p.m. CET. Based on the results of this study and other data, Merck plans to initiate a Phase III clinical study on a once daily dosing regimen of ISENTRESS in early 2014, pending review by regulatory agencies. ISENTRESS is administered twice daily, in accordance with the approved Prescribing Information.

Published
16 October 2013
From
Merck press release
New and experimental HIV treatments
European Commission Approves Gilead Sciences' Tybost(TM), a New Boosting Agent for HIV Therapy

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission has granted marketing authorization for once-daily Tybost(TM) (cobicistat 150 mg tablets), a pharmacokinetic enhancer that boosts blood levels of certain HIV medicines. Tybost is indicated as a boosting agent for the HIV protease inhibitors atazanavir 300 mg once daily and darunavir 800 mg once daily as part of antiretroviral combination therapy in adults with HIV-1 infection.

Published
26 September 2013
From
Gilead press release
TB treatment
Adding Blood Pressure Drug to Standard Antibiotics Speeds Up TB Treatment

Study in mice shows verapamil enhances isoniazid plus rifampin antibiotic therapy.

Published
02 September 2013
From
Johns Hopkins Medicine press release
← Prev1...34567...9Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.